Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Up 610.2% in August

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 21,539 shares, an increase of 610.2% from the August 15th total of 3,033 shares. Based on an average daily volume of 885,605 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Emmaus Life Sciences Stock Performance

Shares of EMMA stock opened at $0.05 on Friday. The stock’s fifty day moving average is $0.03 and its two-hundred day moving average is $0.02. The firm has a market capitalization of $3.62 million, a P/E ratio of -0.57 and a beta of 10.07. Emmaus Life Sciences has a fifty-two week low of $0.01 and a fifty-two week high of $0.09.

Emmaus Life Sciences (OTCMKTS:EMMA) last released its earnings results on Friday, August 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $6.32 million for the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.